Skip to main content
. Author manuscript; available in PMC: 2023 Aug 2.
Published in final edited form as: Stat Biopharm Res. 2022 Aug 2;14(3):270–282. doi: 10.1080/19466315.2022.2081602

Figure 3.

Figure 3.

Simulation results summarized based on 5000 simulated trials under 9 fixed scenarios for each combination trial designs for finding one MTD, including the 3+3 design, the two-dimensional Bayesian logistic regression method (BLRM)32, the partial ordering continual reassessment method (POCRM)20, the copula regression method34, and the Bayesian optimal interval (BOIN) combination design25. Four performance metrics are reported: (a) percentage of correct MTD selection; (b) percentage of patients allocated to MTDs; (c) percentage of overdose selection; and (d) percentage of patients allocated to overdoses, where the overdose is defined as the dose combination that has a DLT probability greater than 33%.